| |
| |
|
| Insider
Information: |
Noyes Timothy P |
| Relationship: |
|
| City: |
Waltham |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
0 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
0 |
|
|
| Total
Value |
$0 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Protara Therapeutics, Inc |
TARA |
President and CEO, Dir... |
2018-02-16 |
0 |
2015-09-08 |
0 |
Premium* |
|
|
Aerovate Therapeutics, Inc. |
AVTE |
|
2024-05-01 |
0 |
2022-11-01 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-05-01 |
4 |
AS |
$19.91 |
$230,946 |
D/D |
(11,357) |
0 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-05-01 |
4 |
OE |
$2.14 |
$21,400 |
D/D |
10,000 |
10,000 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-04-16 |
4 |
AS |
$24.40 |
$246,971 |
D/D |
(10,000) |
0 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-04-16 |
4 |
OE |
$2.14 |
$21,400 |
D/D |
10,000 |
10,000 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-04-01 |
4 |
OE |
$2.14 |
$21,400 |
D/D |
10,000 |
10,000 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-04-01 |
4 |
AS |
$28.96 |
$300,033 |
D/D |
(10,000) |
0 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-07-28 |
4 |
AS |
$18.00 |
$98,604 |
D/D |
(5,478) |
0 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-07-28 |
4 |
OE |
$2.14 |
$11,723 |
D/D |
5,478 |
5,478 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-07-17 |
4 |
AS |
$18.11 |
$81,896 |
D/D |
(4,522) |
0 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-07-17 |
4 |
OE |
$2.14 |
$9,677 |
D/D |
4,522 |
4,522 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-07-03 |
4 |
AS |
$18.00 |
$180,000 |
D/D |
(10,000) |
0 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-07-03 |
4 |
OE |
$2.14 |
$21,400 |
D/D |
10,000 |
10,000 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-05-02 |
4 |
AS |
$21.15 |
$14,657 |
D/D |
(693) |
0 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-05-01 |
4 |
AS |
$20.61 |
$309,089 |
D/D |
(15,000) |
693 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-05-01 |
4 |
OE |
$2.14 |
$32,100 |
D/D |
15,000 |
15,693 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-04-03 |
4 |
AS |
$19.16 |
$290,916 |
D/D |
(15,000) |
0 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-04-03 |
4 |
OE |
$2.14 |
$32,100 |
D/D |
15,000 |
15,000 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-03-01 |
4 |
OE |
$2.14 |
$32,100 |
D/D |
15,000 |
15,000 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-03-01 |
4 |
AS |
$22.71 |
$357,196 |
D/D |
(15,000) |
0 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-02-01 |
4 |
AS |
$22.52 |
$340,197 |
D/D |
(15,000) |
0 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-02-01 |
4 |
OE |
$2.14 |
$32,100 |
D/D |
15,000 |
15,000 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-01-03 |
4 |
AS |
$26.80 |
$406,076 |
D/D |
(15,000) |
0 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2023-01-03 |
4 |
OE |
$2.14 |
$32,100 |
D/D |
15,000 |
15,000 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2022-12-01 |
4 |
AS |
$18.00 |
$270,000 |
D/D |
(15,000) |
0 |
0 |
- |
|
| AVTE |
Aerovate Therapeutics, In... |
CHIEF EXECUTIVE OFFICER |
• • – |
2022-12-01 |
4 |
OE |
$2.14 |
$32,100 |
D/D |
15,000 |
15,000 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
